Abstract
Context of use
• Operationalize the recruitment of patients across the spectrum of disease with mild to severe RA • Measure should have discriminatory power (i.e., able to differentiate between an active treatment and placebo) and not be limited by floor or ceiling effects
Concepts of measurement
• RA-related symptoms discussed 
RESULTS:
Over the course of the workshop, a consensus emerged that there are several outcomes important to RA patients not explicitly assessed by the ACR response criteria (i.e., fatigue, stiffness, and participation). Finally, consensus amongst the various stakeholders was reached that any new measure needs to provide information over and above what is currently captured by the traditional primary composite endpoints and the priority would be to focus on FDA qualification of a PRO measure evaluating RA-related fatigue.
CONCLUSION:
The RA WG is initiating a collaboration with clinical experts through OMERACT to provide an operational definition of fatigue and to develop a conceptual framework to support its measurement in clinical trials. Following this preliminary step, qualitative and quantitative steps will be launched to develop the fatigue measure.
Structure
• Agenda developed in collaboration with C-Path PRO Consortium, FDA, OMERACT representatives, and RA WG co-chairs • Format of the workshop:
• Presentations of existing evidence and current state and opportunities for measuring treatment benefit in RA
• Presenters identified
• Presentations followed by general discussion facilitated by moderator • To identify RA-related symptoms and RA-defining decrements in physical functioning that could be investigated by the RA Working Group for use as patient-reported endpoints in clinical trials to support label claims.
• Expected outcome was a research agenda aimed at collecting evidence for the FDA qualification of one or more PRO instruments that capture concepts that are relevant to patients with RA. Once qualified, the PRO instruments will contribute to the assessment of treatment benefit in RA drug registration trials. 
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